BGT226 (NVP-BGT226) is a novel phosphoinositide 3-kinase/mTOR dual inhibitor. BGT226 (NVP-BGT226) displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
| Cell Experiment | |
|---|---|
| Cell lines | FaDu, Detroit 562, HONE-1 and HONE-1-C15 cells line |
| Preparation method | Growth-inhibition assay. Cells in the logarithmic growth phase were cultured at a density of 5,000 to 20,000 cells per milliliter per well in a 24-well plate. The cells were exposed to various concentrations of BGT226 for 3 generation times. At the end of the incubation period, cells were fixed and stained with 50% ethanol containing 0.5% methylene blue for 30 minutes. The resulting colored residues were dissolved in 1% N-lauroyl-sarcosine, and optical density was read at 550 nm using a microplate reader. The IC50 value resulting from 50% inhibition of cell growth was calculated graphically as a comparison with control groups. Each point represents the average of at least 3 independent experiments run in duplicate. |
| Concentrations | IC50 ranging from 7.4 to 30.1 nmol/L |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | human FaDu xenografted mice |
| Formulation | dissolved in 90% N-methyl-2-pyrrolidone (NMP)/10% PEG300 |
| Dosages | 3.5 and 5mg/kg once a day for 21 consecutive days |
| Administration | orally |
| Molecular Weight | 650.6 |
| Formula | C32H29F3N6O6 |
| CAS Number | 1245537-68-1 |
| Form | Solid |
| Solubility (25°C) | DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
| Related PI3K Products |
|---|
| STX-478
STX-478 is a mutation-selective variant PI3Ka inhibitor for studies related to breast cancer and other solid tumors. |
| Hirsutenone
Hirsutenone is an active botanical diarylheptanoid present in Alnus species and exhibits many biological activities, including anti-inflammatory, anti-tumor promoting and anti-atopic dermatitis effects. Hirsutenone attenuates adipogenesis by binding directly to PI3K and ERK1 in a non-ATP competitive manner. |
| Boc-L-cyclobutylglycine
Boc-L-cyclobutylglycine is a glycine derivative that can be used for PI3K inhibitor synthesis. |
| PI-273
PI-273 is a first reversibly and specific phosphatidylinositol 4-kinase (PI4KIIα) inhibitor with an IC50 of 0.47 μM. PI-273 can inhibit breast cancer cell proliferation, block the cell cycle and induce cell apoptosis. |
| Chaetominine
Chaetominine is an alkaloidal metabolite. Chaetominine has cytotoxicity against human leukemia K562 and colon cancer SW1116 cell lines. Chaetominine reduces MRP1-mediated agent resistance via inhibiting PI3K/Akt/Nrf2 signaling pathway in K562/Adr human leukemia cells. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
